Antibody Discovery News and Research

RSS

Breakthrough: Sequencing functional antibody proteins directly from human blood

Rapid Novor Inc., the world’s leader in mass spectrometry (MS)-based antibody protein sequencing, announced today that its REpAb® antibody discovery platform was used to successfully sequence a complex mixture of functional antibodies directly from the serum of a human patient after receiving a COVID-19 vaccine.

6 Jun 2023

The potential clinical benefit of the Multabody platform as a therapeutic for SARS-CoV-2

The potential clinical benefit of the Multabody platform as a therapeutic for SARS-CoV-2.

26 May 2023

PhenomeX Launches Beacon Select™ Optofluidic System with Opto® B Discovery Workflows

Affordable two-chip Beacon Select system to broaden customer access to innovative high throughput, function-first antibody discovery capabilities.

From PhenomeX 16 May 2023

LabGenius Debuts T-cell Engager Optimisation Capability That Yields Molecules with >400-fold Tumour Killing Selectivity Versus Clinical Benchmark

Through a recent platform demonstration project, LabGenius’ machine learning-driven lead optimisation capability delivered dozens of novel T-cell engagers with best-in-class killing selectivity.

From LabGenius 16 May 2023

Advancing the development of vaccines through recombinant technology

In this interview, News-Medical talks to Dr. Amy Sheng, the head of CRO at Sino Biological, about current developments in the field of vaccine development through recombinant techniques.

From Sino Biological Inc. 4 May 2023

Research uncovers antibodies that are still effective against new variants of SARS-CoV-2

An anonymous San Diego resident has become a fascinating example of how the human immune system fights SARS-CoV-2.

26 Apr 2023

Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform

Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, today announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity.

From Antiverse 1 Mar 2023

Researchers develop AI-based strategy for discovering high-affinity antibody drugs

Scientists at University of California San Diego School of Medicine have developed an artificial intelligence (AI)-based strategy for discovering high-affinity antibody drugs.

30 Jan 2023

Berkeley Lights launches Beacon Select™, a new optofluidic system for cell line development

Berkeley Lights, Inc., a life sciences tools company, today announced the launch of the Beacon Select™, the company's new optofluidic system for cell line development (CLD).

From PhenomeX 19 Jan 2023

High affinity antibodies isolated to safely target Claudin 6-positive tumors

Integral Molecular, the industry leader in antibody discovery for membrane proteins, has published the targeting mechanism enabling best-in-class specificity of its Claudin 6 (CLDN6) antibody CTIM-76 being developed for cancer therapy with Context Therapeutics.

6 Jan 2023

Antibody discovery could explain why so many group A strep vaccines have failed

Researchers at Lund University in Sweden have discovered an antibody with the potential to protect against Strep A infection, as well as a rare form of antibody binding, that leads to an effective immune response against bacteria.

12 Dec 2022

Broadly cross-reactive antibodies that protect from SARS-CoV-2 variants are revealed by virus coldspot-driven discovery

A recent study identified neutralizing antibodies against conserved SARS-CoV-2 epitopes.

30 Nov 2022

Hemagglutinin stem immunogens may hold the key for broad protection against influenza A viruses

Researchers proposed that vaccines targeting the immunosubdominant yet conserved hemagglutinin (HA) stem could trigger broadly neutralizing antibodies (bnAbs) against influenza A viruses.

15 Nov 2022

Study provides a guide to neutralizing Lassa virus using a trio of rare antibodies

A new study from scientists at La Jolla Institute for Immunology (LJI) gives researchers a guide to neutralizing Lassa virus using a trio of rare antibodies isolated from survivors of Lassa virus infection.

26 Oct 2022

Insights into the products and services of Azenta

This interview talks to Andre Kotze about the different services and products available at Azenta.

From Azenta Life Sciences 8 Aug 2022

LJI acquires Carterra LSA instrument to enhance antibody screening and characterization efforts

Carterra, Inc., the world leader in innovative technologies enabling high-throughput biology, and La Jolla Institute for Immunology, a globally recognized non-profit research organization dedicated to understanding the power of the immune system to promote human health, announced today that LJI has acquired a Carterra LSA instrument to enhance its antibody screening and characterization work.

2 Aug 2022

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization (CDMO), today announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.

From PhenomeX 6 Jun 2022

Dotmatics Biology Solution for Antibody Discovery streamlines data collection and workflows to accelerate antibody research and therapies

...

From Dotmatics 5 May 2022

Antibodies that neutralize most sarbecoviruses, including SARS-CoV-2 variants

Researchers isolate three mAbs that broadly neutralized sarbecoviruses and carried out virological and structural studies of these mAbs.

21 Apr 2022

Fortis Life Sciences acquires Abcore, a leader in nanobody technologies

Fortis Life Sciences has acquired Abcore, a San Diego, California, USA based antibody discovery platform specializing in nanobody technology. With the addition of Abcore, Fortis extends its capabilities into the antibody discovery market serving biopharma customers developing antibody and nanobody-based therapeutics.

From Fortis Life Sciences 3 Mar 2022